Galinpepimut-S - Memorial Sloan Kettering Cancer Center/Sellas Life Sciences Group

Drug Profile

Galinpepimut-S - Memorial Sloan Kettering Cancer Center/Sellas Life Sciences Group

Alternative Names: FPI-01; SLS-001; WT-1 analog peptide vaccine; WT1 cancer vaccine - SELLAS Life Sciences; WT1 peptide vaccine - Memorial Sloan Kettering; WT1 vaccine - Memorial Sloan Kettering; ZELTHERVA

Latest Information Update: 17 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Sellas Life Sciences Group
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Acute myeloid leukaemia; Multiple myeloma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Mesothelioma; Multiple myeloma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Fallopian tube cancer; Peritoneal cancer

Most Recent Events

  • 14 Sep 2018 Galinpepimut-S - Memorial Sloan Kettering Cancer Center/Sellas Life Sciences Group receives Orphan Drug status for Multiple myeloma in European Union
  • 20 Jul 2018 Galinpepimut-S - Memorial Sloan Kettering Cancer Center/Sellas Life Sciences Group receives Fast Track designation for Multiple myeloma [SC,Injection] in USA
  • 04 Jun 2018 Interim safety, efficacy and immunogenicity results of phase I trial (Combination therapy) in Ovarian cancer released by SELLAS Life Sciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top